Integrative strategy of testing systems for identification of endocrine disruptors inducing metabolic disorders-an introduction to the OBERON project

dc.contributor.author
Audouze, Karine
dc.contributor.author
Sarigiannis, Denis
dc.contributor.author
Alonso Magdalena, Paloma
dc.contributor.author
Brochot, Celine
dc.contributor.author
Casas Sanahuja, Maribel
dc.contributor.author
Vrijheid, Martine
dc.contributor.author
Babin, Patrick J.
dc.contributor.author
Karakitsios, Spyros
dc.contributor.author
Coumoul, Xavier
dc.contributor.author
Barouki, Robert
dc.date.issued
2021-02-09T07:04:17Z
dc.date.issued
2021-02-09T07:04:17Z
dc.date.issued
2020
dc.identifier
Audouze K, Sarigiannis D, Alonso-Magdalena P, Brochot C, Casas M, Vrijheid M, Babin PJ, Karakitsios S, Coumoul X, Barouki R. Integrative strategy of testing systems for identification of endocrine disruptors inducing metabolic disorders-an introduction to the OBERON project. Int J Mol Sci. 2020; 21(8):2988. DOI: 10.3390/ijms21082988
dc.identifier
1422-0067
dc.identifier
http://hdl.handle.net/10230/46393
dc.identifier
http://dx.doi.org/10.3390/ijms21082988
dc.description.abstract
Exposure to chemical substances that can produce endocrine disrupting effects represents one of the most critical public health threats nowadays. In line with the regulatory framework implemented within the European Union (EU) to reduce the levels of endocrine disruptors (EDs) for consumers, new and effective methods for ED testing are needed. The OBERON project will build an integrated testing strategy (ITS) to detect ED-related metabolic disorders by developing, improving and validating a battery of test systems. It will be based on the concept of an integrated approach for testing and assessment (IATA). OBERON will combine (1) experimental methods (in vitro, e.g., using 2D and 3D human-derived cells and tissues, and in vivo, i.e., using zebrafish at different stages), (2) high throughput omics technologies, (3) epidemiology and human biomonitoring studies and (4) advanced computational models (in silico and systems biology) on functional endpoints related to metabolism. Such interdisciplinary framework will help in deciphering EDs based on a mechanistic understanding of toxicity by providing and making available more effective alternative test methods relevant for human health that are in line with regulatory needs. Data generated in OBERON will also allow the development of novel adverse outcome pathways (AOPs). The assays will be pre-validated in order to select the test systems that will show acceptable performance in terms of relevance for the second step of the validation process, i.e., the inter-laboratory validation as ring tests. Therefore, the aim of the OBERON project is to support the organization for economic co-operation and development (OECD) conceptual framework for testing and assessment of single and/or mixture of EDs by developing specific assays not covered by the current tests, and to propose an IATA for ED-related metabolic disorder detection, which will be submitted to the Joint Research Center (JRC) and OECD community.
dc.description.abstract
The authors would like to acknowledge OBERON (https://oberon-4eu.com/, a project funded by the European Union’s Horizon 2020 research and innovation program under grant agreement no. 825712.
dc.format
application/pdf
dc.format
application/pdf
dc.language
eng
dc.publisher
MDPI
dc.relation
Int J Mol Sci. 2020; 21(8):2988
dc.relation
info:eu-repo/grantAgreement/EC/H2020/825712
dc.rights
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Adverse outcome pathways
dc.subject
Computational systems toxicology
dc.subject
Endocrine disruptors
dc.subject
Integrative approach
dc.subject
Metabolic disorders
dc.subject
Metabolism
dc.subject
Non-alcoholic fatty liver diseases
dc.subject
Non-animal testing; obesity
dc.subject
Predictive toxicology
dc.title
Integrative strategy of testing systems for identification of endocrine disruptors inducing metabolic disorders-an introduction to the OBERON project
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)